Surf Wiki
Save to docs
general/radiation-therapy-procedures

From Surf Wiki (app.surf) — the open knowledge base

TheraSphere

Radiotherapy cancer treatment

Radiotherapy cancer treatment

FieldValue
nameTheraSphere
specialtyinterventional radiology

TheraSphere is a radiotherapy treatment for hepatocellular carcinoma (HCC) that consists of millions of microscopic, radioactive glass microspheres (20–30 micrometres in diameter) being infused into the arteries that feed liver tumors. These microspheres then embolize, lodging themselves in the liver's capillaries and bathing the malignancy in high levels of yttrium-90 radiation. It is currently approved as a Humanitarian Device, meaning effectiveness has not been proven, for patients as a neoadjuvant to surgery or transplantation by the U.S. Food and Drug Administration and is being used at a number of clinical centers in the United States.

Description

TheraSphere consists of insoluble glass microspheres where yttrium-90 is an integral constituent of the glass. Each milligram contains between 22,000 and 73,000 microspheres. Yttrium-90 is a pure beta emitter (physical half-life of 64.2 hours or 2.67 days) and decays to stable zirconium-90. The average energy of the beta emissions from yttrium-90 is 0.9367 MeV.

The Therasphere package insert contains a Black Box warning concerning 5 Pre-treatment high risk factors associated with serious adverse events resulting in 11/12 deaths.

Following embolization of the yttrium-90 glass microspheres in tumorous liver tissue, the beta radiation emitted provides a therapeutic effect. The microspheres are delivered into the liver tumor through a catheter placed into the hepatic artery that supplies blood to the tumor. This is usually performed in a hospital's radiology suite and patients remain conscious throughout the procedure. The microspheres are unable to pass through the vasculature of the liver due to arteriolar capillary blockade and are trapped in the tumor. There they exert a local radiotherapeutic effect with some damage to surrounding normal liver tissue.

Therasphere was issued a Class 2 Device Recall from the FDA in October 2016.

Efficacy

Low-risk patients with unresectable liver cancer appear to gain control over their malignancies for at least 2 years when treated with TheraSphere. They survived a median of 800 days compared with a median of 258 days for high risk patients (P

In a separate study based on follow-up data from 43 treated patients, 20 patients (47%) had an objective tumor response based on percent reduction in tumor size and 34 patients (79%) had a tumor response when percent reduction and/or tumor necrosis were used as a composite measure of tumor response.

References

References

  1. "Advancing Science for Life - US".
  2. "Advancing Science for Life - US".
  3. [http://www.cancercenter.com/conventional-cancer-treatment/therasphere.cfm TheraSphere - Innovative Form of Radiation Therapy for Inoperable Liver Cancer]
  4. "Class 2 Device Recall TheraSphere(R) YTTRIUM90 GLASS MICROSPHERE".
  5. "Untitled Document".
  6. "Advancing Science for Life - US".
Info: Wikipedia Source

This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.

radiation-therapy-procedures
Want to explore this topic further?

Ask Mako anything about TheraSphere — get instant answers, deeper analysis, and related topics.

Research with Mako

Free with your Surf account

Content sourced from Wikipedia, available under CC BY-SA 4.0.

This content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.

Report